- Home
- MRVL vs GSK Comparison
MRVL vs GSK Comparison
Compare MRVL & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRVL | GSK |
|---|---|---|
| Founded | 1995 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | 66841 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0B | 108.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRVL | GSK |
|---|---|---|
| Price | $169.44 | $50.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 32 | 2 |
| Target Price | ★ $120.28 | N/A |
| AVG Volume (30 Days) | ★ 21.7M | 4.0M |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | 0.15% | ★ 3.40% |
| EPS Growth | ★ 400.98 | N/A |
| EPS | ★ 3.07 | N/A |
| Revenue | ★ $8,194,600,000.00 | N/A |
| Revenue This Year | $35.14 | $6.99 |
| Revenue Next Year | N/A | $4.19 |
| P/E Ratio | $52.30 | ★ $32.75 |
| Revenue Growth | ★ 42.09 | N/A |
| 52 Week Low | $58.62 | $35.45 |
| 52 Week High | $175.80 | $61.70 |
Technical Indicators
Market Signals| Indicator | MRVL | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 70.37 | 30.71 |
| Support Level | $73.93 | $49.99 |
| Resistance Level | $170.84 | $51.46 |
| Average True Range (ATR) | 8.95 | 0.81 |
| MACD | -0.82 | -0.52 |
| Stochastic Oscillator | 77.89 | 5.27 |
Price Performance
Historical ComparisonAbout MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.